Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

The hospital has maintained steady revenue of Rs 15-20 crore over the past three years, with a growth rate of around 10%.

The probe agency also attached six immovable properties and froze an amount of Rs 178.12 crore across 73 bank accounts under ...

Noida Traffic Police issues advisory for Printpack India event at India Expo Center in Gautam Budh Nagar- route diversions details ...

1 Day CRBP -2.32% DJIA -0.07% Russell 2K 0.00% Health Care/Life Sciences -0.02% ...

It is time for the private sector to take up the investment baton ... 2024-25 has been budgeted at about 3.3X the capex for 2019-20. In the March quarter, the constraints on new approvals and ...

India’s insurance sector is on a strong growth trajectory and is expected to emerge as the fastest-growing market among G20 nations over the next five years, according to the Economic Survey 2025 ...

SDI Productions / Getty Images A family limited liability company (LLC) is formed by family members ... "In less than 20 years—a meteoric pace unprecedented in the development of business ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 1.54% to $9.88 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite ...

Mutual Advisors LLC reduced its holdings in Capital Group U.S. Multi-Sector Income ETF (NYSEARCA:CGMS – Free Report) by 22.3% in the 4th quarter, according to its most recent 13F filing with the ...

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...